NCT02904603Unknown不适用
Prospective Monitoring of Immune Parameters in Patients With Hepatitis C Under Treatment With Direct Acting Antivirals
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Change of IP10 and related cytokines during treatment (ng/ml)
研究概览
简要总结
Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters and regular laboratory findings.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •written consent, age, HCV-RNA positive, DAA therapy
排除标准
- 未提供
结局指标
主要结局
Change of IP10 and related cytokines during treatment (ng/ml)
时间窗: 24 weeks (observation time under and after DAA therapy)
Screening for Biomarkers under DAA Therapy until timepoint SVR 12 (12 weeks treatment plus control 12 weeks after end of Treatment = 24 weeks)
次要结局
- SVR 12(24 weeks (12 weeks treatment plus control 12 weeks after end of treatment))
- Change of inflammatory markers (ferritin ng/ml, CRP mg/l, PCT ng/ml) during treatment(24 weeks (observation time under DAA therapy))
研究者
Dr. Georg Peschel
Dr. med.
University of Regensburg
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell LymphomaIndolent LymphomaNCT03261349National Taiwan University Hospital21
已完成
不适用
Hepatitis C Virus and the Humoral Immune SystemHepatitis C VirusNCT00219999Rockefeller University161
已完成
不适用
An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis CHepatitis C, ChronicNCT03423641Kaiser Permanente33,808
已完成
2 期
Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCVHepatitis C, ChronicNCT02690103Cairo University37
招募中
不适用
Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer DevelopmentHepatitis C Virus InfectionNCT06718530Centro di Riferimento Oncologico - Aviano1,000
